LASAACI 2024 Fall Symposium

Los Angeles, CA US
September 7, 2024

The Los Angeles Society of Allergy, Asthma and Clinical Immunology (LASAACI) is a CME educational meeting jointly provided by the American College of Allergy, Asthma and Immunology and the LASAACI.  
The 2024 program is a four-hour event with Faculty who are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Los Angeles Society of Allergy, Asthma & Clinical Immunology (LASAACI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…

Updates & Advances in Immunotherapy
1. Recommend opportunities for treatment simplification among existing IT patients, without compromise to clinical outcomes.
2. Chart the clinical benefits of IT using improved strategies for antigen selection and prioritization.
3. Apply tools to engage and retain additional patients on the IT journey. 

Allergy and Asthma Prevention
1. Upon completion of this learning activity, participants should be able to appreciate infant microbiota features that distinguish high and low risk for childhood atopy and asthma development 
2. Upon completion of this learning activity, participants should be able to define a mechanism by which microbial metabolites promote allergic inflammation
3. Upon completion of this learning activity, participants should be able to recognize that infant gut microbiome manipulation is an intervention currently being tested to prevent childhood allergic sensitization

Mast Cell Disorders
1. Discriminate btween the various forms of mast cell activation disease
2. Summarize key aspects of the diagnosis of mast cell activation disease from clinical suspicion to laboratory studies
3. Review clinical data on treatment options for mast cell disorder

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

NO COMMERCIAL SUPPORT WAS RECEIVED FOR THIS ACTIVITY

 

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
09/07/2024
Course expires: 
12/31/2025
Event starts: 
09/07/2024 - 8:30am CDT
Event ends: 
09/07/2024 - 3:30pm CDT
Add to calendar: 
Rating: 
0
Los Angeles Society of Allergy, Asthma & Clinical Immunology  
2024 Fall Symposium
Skirball Cultural Center, Los Angeles CA
Saturday, September 7, 2024

6:30AM-8:20AM    Registration, Exhibits & Coffee Break

8:20AM-8:30AM    WELCOME AND INTRODUCTION
        Sonal Patel, MD, LASAACI President/Program Director
        Session Moderator: Sonal Patel, MD

8:30AM-9:30AM    The Human Microbiota and Asthma and Allergy
        Susan Lynch, PhD

9:30AM-10:30AM    Updates and Advances in Immunotherapy
        Tricia Sowers, PhD

10:30AM-11:30AM    Buffet Brunch, Exhibits, Posters

11:30AM-12:30PM    Brought to you by the American College of Allergy, Asthma & Immunology: Transforming Traditional Allergy Care
        Tania Elliott, MD, FAAAAI, FACAAI

12:30PM-1:30PM    Mast Cell Activation Syndrome: How did we get here?
        Katharine M. Woessner, MD, FAAAAI

1:30PM        Adjourn

Skirball Cultural Center
2701 N. Sepulveda Blvd
Los Angeles, CA 90049
United States

All relevant financial relationships with ineligible companies have been mitigated.

Tania Elliott, MD – Speaker
Consultant: AstraZeneca

Susan Lynch, PhD – Speaker
Advisor: Siolta Therapeutics Inc.; Consultant: Atria Institute, Siolta Therapeutics Inc.; Ownership interest: Siolta Therapeutics Inc.; Royalties or patent beneficiary: Siolta Therapeutics Inc.; Stock/options: Siolta Therapeutics Inc.

Tricia Sowers, PhD – Speaker
Consultant: Accu-Mix, ALK-Abello

Katharine M. Woessner, MD – Speaker
Consultant: AstraZeneca, GSK; Speaker: Amgen, AstraZeneca, GSK, Sanofi, Takeda

Sonal Patel, MD – Planner, Moderator
Advisor: Sanofi; Speaker: Regeneron

Jonathan Corren, MD – Planner
Advisor: AstraZeneca, Regeneron, Sanofi; Independent contractor: Novartis, Regeneron; Researcher: AstraZeneca; Speaker: AstraZeneca, GSK, Novartis, Regeneron, Speaker

Rita Kachru, MD – Planner
Researcher: Aimmune

The following have no relevant financial relationships with ineligible companies to disclose:

Sheila M. Bonilla, MD – Planner
Edward Hu, MD – Planner
Caroline Spagnola, MD – Planner
Andrew K. Wong, MD – Planner
Joseph Yusin, MD – Planner
Karol Anderson – Planner

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.